Eton Pharmaceutical
ETON
60.85
-0.51
-0.83%
Eton Pharmaceutical
US · ETON
#2944 by market cap
Listed 2018
60.85
-0.51
-0.83%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 45 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 74.21% +2.29pp
- Institutions
- 233 +45
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund37.70%
Hedge Fund29.53%
Individual/Insider4.88%
Public Company3.42%
Private Company1.32%
Insurance Company1.11%
Sovereign Wealth Fund0.66%
Government Pension Fund0.38%
Other20.91%
Top holders as of 2026-09-30
Opaleye Management Inc.
8.46% · 2.44M sh
EcoR1 Capital, LLC
7.53% · 2.17M sh
BlackRock
7.27% · 2.10M sh
Vanguard Capital Management, LLC
4.17% · 1.20M sh
Nantahala Capital Management, LLC
4.08% · 1.18M sh
Sean Brynjelsen
3.33% · 961.19K sh
FMR
2.86% · 823.45K sh
Morgan Stanley
2.63% · 751.03K sh
State Street Global Advisors
2.69% · 775.54K sh
Geode Capital Management, LLC
2.65% · 764.40K sh
Oberweis Asset Management, Inc.
1.75% · 501.60K sh
Morgan Stanley Investment Management Inc.
1.78% · 513.17K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Sean Brynjelsen | Chief Executive Officer | 3.33% |
| Norbert Riedel | Independent Chairperson | 0.78% |
| Paul Maier | Independent Director | 0.25% |
| Charles Casamento | Independent Director | 0.24% |
| David Krempa | Chief Business Officer | 0.15% |
| Danka Radosavljevic | Chief Operating Officer | 0.08% |
| James Gruber | Consultant | 0.06% |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer | 0.00% |
| Opaleye Management Inc. | -- | -- |
| Jennifer Adams | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Charles Casamento | Independent Director | Derivative Exercise and Sale | -80,555 | $3.58–67.87 |
| 2026-11-09 | Ipek Erdogan-Trinkaus | Chief Commercial Officer | Derivative Exercise and Sale | -3,500 | $15.47–67.88 |
| 2026-10-05 | David Krempa | Chief Business Officer | Derivative Exercise and Sale | -4,166 | $55.07 |
| 2026-10-05 | David Krempa | Chief Business Officer | Intent to Sell (Form 144) | -4,166 | $55.07 |
| 2026-10-01 | David Krempa | Chief Business Officer | Derivative Exercise and Retained | +6,356 | -- |
| 2026-08-27 | Paul Maier | Independent Director | Derivative Exercise and Sale | -50,000 | $3.78–61.77 |
| 2026-08-27 | Paul Maier | Independent Director | Other Derivative Acquisition | +12,500 | $7.31 |
| 2026-08-27 | Paul Maier | Independent Director | Derivative Exercise and Retained | +12,500 | $7.31 |
| 2026-08-23 | David Krempa | Chief Business Officer | Derivative Exercise and Sale | -25,000 | $7.31–65.07 |
| 2026-08-19 | Sean Brynjelsen | Chief Executive Officer | Open Market Disposition | -100,000 | $60.17–62.65 |
| 2026-08-18 | Sean Brynjelsen | Chief Executive Officer | Intent to Sell (Form 144) | -100,000 | $63.43 |
| 2026-07-30 | Paul Maier | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Charles Casamento | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Norbert Riedel | Independent Chairperson | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | David Krempa | Chief Business Officer | Other Derivative Acquisition | +128,985 | -- |
| 2026-07-30 | Jennifer Adams | Independent Director | Other Derivative Acquisition | +10,000 | -- |
| 2026-07-30 | Judith Matthews | Chief Financial Officer & Secretary | Other Derivative Acquisition | +32,246 | -- |
| 2026-07-30 | Danka Radosavljevic | Chief Operating Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-07-30 | Ipek Erdogan-Trinkaus | Chief Commercial Officer | Other Derivative Acquisition | +80,000 | -- |
| 2026-07-13 | Opaleye Management Inc. | -- | Open Market Disposition | -28,315 | $37.54 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Eton Pharmaceutical discussion 0 comments